A dosing regimen that looks reasonable on paper can still fail
A resident picks a dose, a dosing interval, sees the peak concentration clear the MIC by a healthy margin, and moves on. It's an intuitive way to think about antibiotic dosing, and it's also, for a large fraction of drug classes, the wrong metric to optimize. Time-dependent antibiotics like most beta-lactams don't care how high the peak goes once it clears the target; what predicts efficacy is how long the concentration stays above the minimum inhibitory concentration (MIC) across the dosing interval, expressed as %T>MIC. Concentration-dependent classes like aminoglycosides and fluoroquinolones instead track the ratio of total drug exposure to MIC, AUC/MIC, largely independent of the exact shape of the concentration-time curve. Picking the wrong index to optimize for a given antibiotic class is one of the most common and consequential dosing mistakes in practice.
The pharmacokinetic model underneath the numbers
A one-compartment model with first-order elimination is the workhorse here. Given a dose D delivered at interval tau into a volume of distribution V_d, with a half-life T1/2 (from which the elimination rate constant k = ln(2)/T1/2 follows), the steady-state peak and trough concentrations are:
Cmax_ss = (D / V_d) * (1 / (1 - e^(-k*tau)))
Cmin_ss = Cmax_ss * e^(-k*tau)
AUC_24h = (D / V_d) * (24 / tau) * (1 / k) * (1 - e^(-k*tau))
V_d itself usually scales with patient weight, so a regimen tuned on a 70 kg reference patient can drift out of range for a 100 kg patient without a weight-based adjustment — which is exactly why patient weight sits alongside dose and interval as an input rather than being baked into a fixed V_d.
Once you have the concentration-time curve, the PK/PD index depends on drug class. For a time-dependent beta-lactam, you compute the fraction of the interval tau during which concentration stays above the target MIC. For a concentration-dependent aminoglycoside, you instead compare AUC_24h/MIC against a reference AUC/MIC target, typically in the range of 80-125 depending on the specific pathogen and drug.
Worked example: adjusting an aminoglycoside regimen
Consider a hypothetical aminoglycoside with V_d = 0.25 L/kg in a 70 kg patient (giving V_d = 17.5 L), a half-life T1/2 of 2.5 hours, dosed at D = 400 mg every tau = 24 h, against a pathogen with MIC = 1 mg/L and a reference AUC/MIC target of 100.
Working through the model: k = ln(2)/2.5, approximately 0.277 per hour. Over a 24-hour interval with a single dose, AUC_24h works out to roughly (400/17.5) times (1/0.277) times a factor close to 1.0, giving about 83 mg times h per L. Dividing by MIC = 1 mg/L gives a PK/PD index value of about 83, which falls short of the reference AUC/MIC target of 100.
Steady Cmax comes out around 22.9 mg/L, since the exponential decay term is close to zero for once-daily dosing at this half-life, so Cmax_ss is approximately D/V_d. Steady Cmin is negligible, essentially near zero, which is expected and desirable for aminoglycosides where trough-related nephrotoxicity is the dose-limiting concern. Target met would read false here.
Bumping the dose to 480 mg while keeping the same 24 h interval scales AUC_24h linearly, since the model is linear in dose: the new PK/PD index value comes out to roughly 83 times (480/400), or about 99.6, right at the reference target, with target met flipping to true. This is the kind of adjustment the model makes easy to explore: for a concentration-dependent drug at a fixed interval, dose and AUC/MIC scale together almost one-to-one, so a shortfall of 17% in the index maps cleanly onto a 20% dose increase.
Contrast that with a time-dependent beta-lactam scenario. If %T>MIC is short because the dosing interval tau is too long relative to the half-life, increasing the dose barely helps, since a taller peak decays back down to MIC in only a slightly longer time — the curve is exponential, not linear, near the MIC crossing. Shortening tau, meaning more frequent dosing or a continuous infusion, is almost always the more effective lever for time-dependent classes.
Where regimens go wrong in practice
The single biggest error is applying the wrong optimization target for the antibiotic class. Treating a beta-lactam like a concentration-dependent drug and pushing the dose up to maximize Cmax does little for efficacy and mostly adds toxicity risk, while treating an aminoglycoside like a time-dependent drug and giving smaller, more frequent doses can undershoot the AUC/MIC target that actually predicts kill.
The second error is ignoring renal function's effect on half-life. T1/2 in the model is patient-specific, not a textbook constant; in a patient with reduced clearance, the effective half-life can be two to three times the reference value, which inflates both steady Cmax and AUC_24h at a fixed dose and interval. A regimen validated against a target MIC in a patient with normal renal function can become toxic in one with impaired clearance without any change to the prescribed dose at all.
The third is neglecting that volume of distribution V_d itself shifts with physiological state. Sepsis, burns, and third-spacing can expand V_d well beyond the weight-based estimate, diluting peak concentrations and threatening %T>MIC even when the dose and interval look adequate on paper for a "normal" patient. This is a common reason a regimen that worked on day one of an ICU stay stops working by day three.
Why antibiotic class changes the whole calculation
It's worth being explicit about why the same underlying one-compartment model produces such different dosing strategies depending on antibiotic class. The distinction traces back to the postantibiotic effect, the period after concentration drops below MIC during which bacterial regrowth is still suppressed. Aminoglycosides and fluoroquinolones exhibit a substantial postantibiotic effect, which is exactly why a strategy built around a large, infrequent dose that maximizes AUC/MIC still works even though concentration spends much of the dosing interval tau below MIC; the drug keeps suppressing growth for a while after it's technically "gone." Most beta-lactams have little to no postantibiotic effect against gram-negative organisms, which is why %T>MIC, not AUC/MIC, correlates with outcome for that class: once concentration drops below MIC, regrowth resumes almost immediately, so the interval tau needs to be short enough, or the infusion long enough, to keep concentration above MIC for most of the dosing cycle.
This also explains why extended and continuous infusion strategies for beta-lactams have gained traction clinically. Instead of a bolus dose every tau hours that spikes Cmax and then decays, spreading the same total daily dose D as a continuous or extended infusion keeps concentration close to a flat line just above MIC, maximizing %T>MIC for a given total drug exposure. The tradeoff is practical: continuous infusion requires dedicated IV access and stability of the drug in solution over many hours, which isn't always feasible outside specific care settings. Modeling the standard bolus regimen first, as in the worked example above, is still the right starting point for understanding whether a patient is a good candidate for the more logistically demanding extended-infusion approach.
None of this is a substitute for clinical judgment, therapeutic drug monitoring, or institutional dosing protocols. It's a way to reason quickly about which lever, dose, interval, or reference AUC/MIC target actually moves the needle before more precise patient-specific data is available.
Try the model yourself
Running these calculations by hand for every dosing scenario doesn't scale, especially once you start varying antibiotic class, half-life, and patient weight together. Try the Antibiotic PK/PD MIC AUC %T>MIC Simulator here to see steady Cmax, steady Cmin, and the PK/PD index update in real time as you adjust dose and interval. For related physiological modeling, the biomedical signal tool covers a different but complementary corner of quantitative biomedical analysis.
Top comments (0)